Zurueck zur Suche

Reporte zur Charge U030591

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

12Reporte angezeigt
0Todesfaelle
0Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
ME 5 PA 2 NY 1 WV 1 IN 1 MD 1

VAERS 2223283

MERCK & CO. INC. · MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) · Charge U030591

schwer
Staat
NY
Alter
15,0
Geschlecht
F
Eingang
08.04.2022
Impfdatum
08.04.2022
Beginn
08.04.2022
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: ja Erholt: nein
Eye movement disorder Seizure Syncope

Symptomtext

Following injection a few minutes later patient had an episode of syncope, pt became alert following this, then subsequently eyes rolled back in head, started convulsing for about 30-45 seconds, following seizure VSS, alert and oriented, pt transferred to ER

Weitere VAERSDATA-Felder
Praegender Schweregrund
Seizure
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
none
Vorgeschichte
ADHD
Andere Medikamente
none
Allergien
none
Vorherige Impfungen
-

VAERS 2408438

MERCK & CO. INC. · MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) · Charge U030591

mild
Staat
PA
Alter
5,0
Geschlecht
M
Eingang
11.08.2022
Impfdatum
08.08.2022
Beginn
09.08.2022
Tage bis Beginn
1,0
Dosis
2
Route/Site
SC / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Erythema Pain in extremity Peripheral swelling Skin warm

Symptomtext

Red, swollen, warm, and painful left arm from his kinrix 2 days ago. Approximately 3 inches around. No fever present.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Pain in extremity
Hospital-Tage
-
Labordaten
none
Aktuelle Erkrankungen
none
Vorgeschichte
none
Andere Medikamente
none
Allergien
none
Vorherige Impfungen
-

VAERS 2622902

MERCK & CO. INC. · MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) · Charge U030591

gering
Staat
WV
Alter
-
Geschlecht
U
Eingang
28.04.2023
Impfdatum
31.03.2023
Beginn
31.03.2023
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Expired product administered No adverse event

Symptomtext

No symptomatic adverse event reported; nurse reporting administration of expired PROQUAD; This spontaneous report was received from a nurse referring to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 31-MAR-2023, the patient was vaccinated with expired dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) subcutaneous injection, 0.5 milliliter once, lot #U030591, expiration date: 29-MAR-2023, administered for prophylaxis (strength, and route of administration were not provided) (expired product administered). No temperature excursions were reported. No additional adverse events were reported.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2608338

MERCK & CO. INC. · MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) · Charge U030591

gering
Staat
IN
Alter
1,1
Geschlecht
F
Eingang
03.04.2023
Impfdatum
01.04.2023
Beginn
01.04.2023
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / RL
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Expired product administered

Symptomtext

Patient given an expired vaccine

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
N/A
Vorgeschichte
N/A
Andere Medikamente
N/A
Allergien
NKDA
Vorherige Impfungen
-

VAERS 2357293

MERCK & CO. INC. · MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) · Charge U030591

gering
Staat
ME
Alter
-
Geschlecht
U
Eingang
04.07.2022
Impfdatum
01.06.2022
Beginn
01.06.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
No adverse event Product storage error

Symptomtext

no adverse event; HCP called in to report a temperature excursion on VARIVAX and PROQUAD. HCP reports that 9 patients were administered VARIVAX. HCP reports that the VARIVAX administrations occurred on 6/21/22, 6/23/22, 6/27/22, and 6/28/22. The patients involved in t; This spontaneous report was received from the medical assistant and refers to a patient of an unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On an unspecified date in June 2022, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (recombinant human albumin) subcutaneous injection, lot #U030591, expiration date: 29-MAR-2023, for prophylaxis (dose, strength, route of administration and anatomical location were not provided). The vaccine was administered after the temperature excursion (product storage error). No additional adverse event reported. This is one of the 14 reports from the same reporter.; Sender's Comments: US-009507513-2206USA008492:

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2357285

MERCK & CO. INC. · MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) · Charge U030591

gering
Staat
ME
Alter
-
Geschlecht
U
Eingang
04.07.2022
Impfdatum
01.06.2022
Beginn
01.06.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
No adverse event Product storage error

Symptomtext

no adverse event; HCP called in to report a temperature excursion on VARIVAX and PROQUAD. HCP reports that 9 patients were administered VARIVAX. HCP reports that the VARIVAX administrations occurred on 6/21/22, 6/23/22, 6/27/22, and 6/28/22. The patients involved in t; This spontaneous report was received from the medical assistant and refers to a patient of an unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On an unspecified date in June 2022, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (recombinant human albumin) subcutaneous injection, lot #U030591, expiration date: 29-MAR-2023, for prophylaxis (dose, strength, route of administration and anatomical location were not provided). The vaccine was administered after the temperature excursion (product storage error). No additional adverse event reported. This is one of the 14 reports from the same reporter.; Sender's Comments: US-009507513-2206USA008492:

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2357284

MERCK & CO. INC. · MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) · Charge U030591

gering
Staat
ME
Alter
-
Geschlecht
U
Eingang
04.07.2022
Impfdatum
01.06.2022
Beginn
01.06.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
No adverse event Product storage error

Symptomtext

no adverse event; HCP called in to report a temperature excursion on VARIVAX and PROQUAD. HCP reports that 9 patients were administered VARIVAX. HCP reports that the VARIVAX administrations occurred on 6/21/22, 6/23/22, 6/27/22, and 6/28/22. The patients involved in t; This spontaneous report was received from the medical assistant and refers to a patient of an unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On an unspecified date in June 2022, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (recombinant human albumin) subcutaneous injection, lot #U030591, expiration date: 29-MAR-2023, for prophylaxis (dose, strength, route of administration and anatomical location were not provided). The vaccine was administered after the temperature excursion (product storage error). No additional adverse event reported. This is one of the 14 reports from the same reporter.; Sender's Comments: US-009507513-2206USA008492:

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2357283

MERCK & CO. INC. · MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) · Charge U030591

gering
Staat
ME
Alter
-
Geschlecht
U
Eingang
04.07.2022
Impfdatum
01.06.2022
Beginn
01.06.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
No adverse event Product storage error

Symptomtext

no adverse event; HCP called in to report a temperature excursion on VARIVAX and PROQUAD. HCP reports that 9 patients were administered VARIVAX. HCP reports that the VARIVAX administrations occurred on 6/21/22, 6/23/22, 6/27/22, and 6/28/22. The patients involved in t; This spontaneous report was received from the medical assistant and refers to a patient of an unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On an unspecified date in June 2022, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (recombinant human albumin) subcutaneous injection, lot #U030591, expiration date: 29-MAR-2023, for prophylaxis (dose, strength, route of administration and anatomical location were not provided). The vaccine was administered after the temperature excursion (product storage error). No additional adverse event reported. This is one of the 14 reports from the same reporter.; Sender's Comments: US-009507513-2206USA008492:

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2357281

MERCK & CO. INC. · MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) · Charge U030591

gering
Staat
ME
Alter
-
Geschlecht
U
Eingang
04.07.2022
Impfdatum
01.06.2022
Beginn
01.06.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
No adverse event Product storage error

Symptomtext

no adverse event; HCP called in to report a temperature excursion on VARIVAX and PROQUAD. HCP reports that 9 patients were administered VARIVAX. HCP reports that the VARIVAX administrations occurred on 6/21/22, 6/23/22, 6/27/22, and 6/28/22. The patients involved in t; This spontaneous report was received from the medical assistant and refers to a patient of an unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On an unspecified date in June 2022, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (recombinant human albumin) subcutaneous injection, lot #U030591, expiration date: 29-MAR-2023, for prophylaxis (dose, strength, route of administration and anatomical location were not provided). The vaccine was administered after the temperature excursion (product storage error). No additional adverse event reported.; Sender's Comments: US-009507513-2206USA008805: US-009507513-2206USA008806: US-009507513-2206USA008807: US-009507513-2206USA008808: US-009507513-2206USA008809: US-009507513-2206USA008810: US-009507513-2206USA008811: US-009507513-2206USA008804: US-009507513-2206USA008802: US-009507513-2206USA008801: US-009507513-2206USA008800: US-009507513-2206USA008799: US-009507513-2206USA008803:

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2215534

MERCK & CO. INC. · MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) · Charge U030591

gering
Staat
PA
Alter
-
Geschlecht
U
Eingang
05.04.2022
Impfdatum
28.02.2022
Beginn
28.02.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
No adverse event Product administered to patient of inappropriate age

Symptomtext

No additional AE; Inbound call from HCP stating a dose of PROQUAD was inadvertently administered to a patient over 13 years of age. No additional AE details or PQC.; This spontaneous report was received from a pharmacist referring to a 13-year-old patient. The patient's medical history, historical drugs, concurrent conditions and concomitant medications were not provided. On 28-FEB-2022, reported as about a month ago, the patient was inadvertently vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (rHA)(PROQUAD) 0.5 milliliter, lot # U030591, expiration date 29-MAR-2023 (route of administration not reported) for prophylaxis (product administered to patient of inappropriate age). The vaccine was reconstitued with sterile diluent, lot number T0143000, expiration date 12-MAR-2022. No adverse event was reported. Lot number T0143000 is an invalid lot number for sterile diluent. Lot number T0143000 does not match any Company product as confirmed by Lot Verification team.

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
STERILE DILUENT
Allergien
-
Vorherige Impfungen
-

VAERS 2212937

MERCK & CO. INC. · MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) · Charge U030591

gering
Staat
MD
Alter
-
Geschlecht
U
Eingang
02.04.2022
Impfdatum
03.03.2022
Beginn
03.03.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect route of product administration

Symptomtext

No additional AEs reported.; a patient was administered PROQUAD intramuscularly instead of subcutaneously.; This spontaneous report was received from a nurse referring to a patient with unknown age and gender. The patient's concurrent condition, pertinent medical history, concomitant medication, drug reactions or allergies were not reported. On 03-MAR-2022, the patient was administered measles, mumps, rubella and varicella (oka-merck) virus vaccine live (recombinant Human albumin (rHA)) (PROQUAD) (0.5 milliliter, lot #U030591, expiration date: 29-MAR-2023, strength was not provided) for prophylaxis intramuscularly instead of subcutaneously (inappropriate route of vaccination). No additional adverse event reported.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect route of product administration
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2206766

MERCK & CO. INC. · MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) · Charge U030591

gering
Staat
-
Alter
5,0
Geschlecht
F
Eingang
30.03.2022
Impfdatum
29.03.2022
Beginn
01.03.2022
Tage bis Beginn
-
Dosis
N/A
Route/Site
SC / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Extra dose administered Nasal congestion

Symptomtext

Patient did not need these vaccines as she had received them on 10/12/2021 Child without fever/ pain/ side effects as of 3/30/22 when event noted.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Extra dose administered
Hospital-Tage
-
Labordaten
N/A
Aktuelle Erkrankungen
Per mom - child has nasal congestion 3/30/22
Vorgeschichte
None *Had received MMRV and DTAP/IPV 10/21
Andere Medikamente
None - was Rx Claritin that day to use if needed for allergy season
Allergien
N/A
Vorherige Impfungen
-